Actively Recruiting
Development of a Mobile Health Intervention for Electronic Cigarette Use Among Young Adults
Led by University of Chicago · Updated on 2026-04-27
46
Participants Needed
1
Research Sites
66 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Electronic Nicotine Delivery Systems (ENDS) use remains prevalent among young adults, and many have high interest in quitting, yet research on effective intervention is lacking. A mobile health (mHealth) intervention that translates effective smoking cessation materials and pharmacotherapy may be a promising avenue for intervention. The initial phase of the proposed study uses a pilot study to evaluate a novel mHealth intervention for young adult ENDS and dual product (ENDS and combustible cigarette) users.
CONDITIONS
Official Title
Development of a Mobile Health Intervention for Electronic Cigarette Use Among Young Adults
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 26 years old, able to understand English, and willing to provide informed consent
- Current ENDS user, using at least 4 out of 7 days per week for the past month
- Interested in quitting or reducing ENDS use (at least 6 out of 10 on interest scale)
- No major psychiatric disorder in past year, including severe alcohol or substance use disorder (except tobacco use disorder), schizophrenia, bipolar disorder, or obsessive compulsive disorder
- For women, not pregnant, not planning pregnancy, and not breastfeeding
- Not currently using smoking cessation medication such as Varenicline or Bupropion
- No history of adverse reactions to nicotine replacement therapy
You will not qualify if you...
- Does not own a mobile phone or unwilling to receive text messages
- No interest in quitting or reducing ENDS use
- Uses electronic cigarettes less than 4 days per week in the past month
- Reports serious psychiatric illness in past year including severe alcohol or substance use disorder (excluding tobacco use disorder), schizophrenia, bipolar disorder, or obsessive compulsive disorder
- Currently using smoking cessation medications including Varenicline or Bupropion
- Female who is pregnant, nursing, or planning to become pregnant within 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Chicago BREATHE Laboratory
Chicago, Illinois, United States, 60637
Actively Recruiting
Research Team
E
Emma Brett, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here